Description
LOOKING FOR CE-CREDITS? VISIT OUR CE-PLATFORM CE-GO TO PURCHASE THIS WEBINAR AS A CE-ELIGIBLE SELF-PACED COURSE.
Welcome to the ISPS-US webinar recordings store! At ISPS-US, we're dedicated to promoting psychological and social approaches to psychosis, transforming the mental health system. As a member, you gain exclusive benefits, including free access to all our webinars. Join our community of like-minded individuals by becoming a member and support our mission. Membership starts at just $6.67 per month and includes free access to our webinar store (log-in to see the discount.)
Webinar Description:
Part 1: David Kimhy, PhD - The Benefits of Physical Exercise on Negative Symptoms
Negative symptoms are highly prevalent among individuals with schizophrenia and related disorders and have been linked to sedentary behaviors and poor aerobic fitness, suggesting a potential target for treatment development. In this presentation, I will review the research literature on the various exercise interventions employed among individuals with schizophrenia and related disorders, along with issues related to their application and feasibility. Next, I will review some of the neurobiological benefits of physical exercise and their relevance to brain circuitry underlying negative symptoms (i.e., neural reward-related pathways). Drawing on recent research publications, I will provide a detailed review of the benefits of moderate-to-vigorous and none-to-low intensity physical exercise interventions in alleviating negative symptoms. Finally, I will provide practical recommendations for the employment of physical exercise interventions among individuals with schizophrenia and related disorders to target negative symptoms.
Part 2: David Kimhy, PhD – Use of Digital Technologies in the Assessment of Negative Symptoms & The Benefits of Physical Exercise on Negative Symptoms
Negative symptoms are highly prevalent among individuals with schizophrenia and related disorders and have been linked to poor functioning and disability. Traditionally, these symptoms have been evaluated via in-person clinical interviews and observations. However, technological advances over the past 15 years have ushered the promise of employing digital technologies to enhance the assessment of negative symptoms. In this presentation, I will describe some of the challenges associated with traditional assessment methods of negative symptoms. Next, I will review emerging research on the use of digital technologies (e.g., actigraphy, smartphones, audio and video recordings of speech and facial expressions) in the assessment of negative symptoms. Finally, I will discuss future directions for research and clinical use in this area.
Presenter Bios:
David Kimhy, PhD
Dr. David Kimhy is a clinical psychologist and a digital mental health entrepreneur with expertise in the development of cognitive and behavioral treatments for serious mental illness. He has more than 20 years' experience designing and leading randomized clinical trials focusing on the use of cognitive and behavioral interventions and technology-based approaches in the assessment and treatment of serious mental illness. This work resulted in more than 90 peer-reviewed research articles, book chapters, and books.
Most recently Dr. Kimhy served as an Associate Professor (tenured) at the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, the Director of the Experimental Psychopathology Laboratory, and the Program Leader for New Interventions in Schizophrenia. He pioneered the use of digital mobile health technologies in the study of psychosis, having published the first studies validating the use of digital phenotyping of patients with schizophrenia and its integration with wearable sensor technologies. His research has been funded by grants from the National Institute of Mental Health, the VA Administration, as well as private and institutional funding.
Dr. Kimhy is the founder and principal of Vital Psychological Therapeutics, the first national telehealth-based psychotherapy practice dedicated to the treatment of individuals with psychosis.
